Atria Wealth Solutions Inc. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 19.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,933 shares of the company's stock after selling 1,229 shares during the period. Atria Wealth Solutions Inc.'s holdings in IDEXX Laboratories were worth $2,039,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of IDXX. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock worth $29,000 after acquiring an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth $31,000. Ashton Thomas Securities LLC purchased a new position in IDEXX Laboratories in the 3rd quarter worth $37,000. Finally, Crews Bank & Trust purchased a new position in IDEXX Laboratories in the 4th quarter worth $41,000. Hedge funds and other institutional investors own 87.84% of the company's stock.
In related news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,330 shares of company stock worth $6,161,276 in the last ninety days. Insiders own 2.11% of the company's stock.
A number of equities analysts recently issued reports on the company. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Finally, Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $533.75.
Check Out Our Latest Report on IDXX
Shares of IDEXX Laboratories stock traded down $0.09 on Friday, hitting $452.77. The company's stock had a trading volume of 773,207 shares, compared to its average volume of 773,580. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a market capitalization of $37.08 billion, a price-to-earnings ratio of 42.43, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The firm has a fifty day moving average price of $431.92 and a 200-day moving average price of $452.28.
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.